Ustekinumab: a guide to its use in plaque psoriasis
Drugs & Therapy Perspectives, 07/19/2012
Keating GM et al. – Subcutaneous ustekinumab (Stelara) improves symptoms in patients with moderate to severe plaque psoriasis and is more effective than etanercept. Subcutaneous ustekinumab is generally well tolerated, with infections being the most commonly reported adverse event.